# HC010 in First-line PD-L1 Positive Advanced NSCLC Patients

Source: https://onco.cc/trials/nct07169552/  
OnCo record `nct07169552` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HC010 in non-small-cell lung cancer, run by HC Biopharma Inc., now recruiting.

## Summary

HC010 in First-line PD-L1 Positive Advanced NSCLC Patients is a phase 2 interventional study registered as NCT07169552 by HC Biopharma Inc., with 50 participants planned, started 2025-12-09 and due to reach its primary completion in 2026-12-30. Interventions recorded: HC010.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07169552
- Phase: 2
- Setting: A Multicenter, Single-arm, Open-label Phase II Clinical Study to Evaluate the Efficacy and Safety of HC010 for Injection in the First-line Treatment of Advanced Non-small Cell Lung Cancer Positive for Programmed Death Ligand-1 (PD-L1)
- Sponsor: HC Biopharma Inc.
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT07169552: https://clinicaltrials.gov/study/NCT07169552

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct07169552.json